Clinical Research Directory
Browse clinical research sites, groups, and studies.
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
Sponsor: Peking University People's Hospital
Summary
To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.
Official title: Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma
Key Details
Gender
FEMALE
Age Range
17 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
82
Start Date
2023-01-06
Completion Date
2025-10-31
Last Updated
2024-07-11
Healthy Volunteers
No
Interventions
Medroxyprogesterone acetate + Atorvastatin
MPA (at a dosage of 250-500 mg/day,) + Atorvastatin (at a dosage of 20 mg/day), by mouth,
Locations (1)
Wang Jianliu
Beijing, Beijing Municipality, China